Abstract 1463P
Background
Chemotherapy in combination with anti-PD-1/PD-L1 antibodies (chemoimmunotherapy) has become the standard treatment for advanced non-small cell lung cancer (NSCLC). Our previous studies highlighted that low baseline concentrations of IL-6 in plasma specimens or tumor tissues responded better to anti-PD-1/PD-L1 immunotherapy alone. However, the role of baseline IL-6 levels in predicting responses to chemoimmunotherapy and the development of resistance to chemoimmunotherapy has not been fully understood yet.
Methods
To confirm the predictive value of IL-6 in the baseline plasma, we conducted an enzyme-linked immunosorbent assay (ELISA) in a group of 123 advanced NSCLC patients who received chemoimmunotherapy. Next, we evaluated the role of IL-6 in chemoimmunotherapy resistance and the underlying mechanisms in mouse models of both lung adenocarcinoma and lung squamous cell carcinoma.
Results
Based on our cohort of 123 NSCLC patients, we found that patients with progressive disease had a higher baseline level of IL-6 in their plasma. Additionally, the potential predictive value of the baseline level of IL-6 in plasma samples for responses was confirmed with area under curve (AUC) up to 0.677. Patients with a low baseline concentration of IL-6 also had a longer progression-free survival and overall survival, with a cut-off value of 7.002 obtained from receiver operating characteristic curve (ROC). Meanwhile, univariate and multivariate Cox regression analyses revealed that baseline IL-6 level in plasma samples was an independent prognostic predictor. Further experiments in mouse models showed that overexpression of IL-6 weakened the anti-tumor effects of immunotherapy in combination with chemotherapy. Immunohistochemical studies also revealed that CD8+ T cells decreased while M2 macrophages, regulating T cells, and myeloid-derived suppressor cells infiltration increased in the IL-6 overexpressing group.
Conclusions
Our study highlights the potential of baseline IL-6 levels as a useful predictive biomarker for chemoimmunotherapy in NSCLC. IL-6 promotes an immunosuppressive tumor microenvironment, suggesting that targeting IL-6 could be a promising approach for cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1401P - Impact of KRAS mutation on non-small cell lung cancer survival outcomes
Presenter: Quentin Thomas
Session: Poster session 20
1402P - Real-world routine KRAS testing practices in France for patients (pts) with advanced or metastatic (AM) non-small cell lung cancer (NSCLC): Data from the ESME cohort
Presenter: Clarisse Audigier Valette
Session: Poster session 20
1403P - Sotorasib in KRAS p.G12C mutated advanced NSCLC: Real-word data from the Italian Expanded Access Program
Presenter: Maria Lucia Reale
Session: Poster session 20
1404P - Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU)
Presenter: Herve Lena
Session: Poster session 20
1405P - Sotorasib in KRAS G12C-mutated NSCLC: A multicenter real-world experience from the expanded access program in Germany
Presenter: Friederike Althoff
Session: Poster session 20
1406P - Outcomes of patients with metastatic EGFR mutant lung cancer requiring dose modifications of first line osimertinib
Presenter: J. Connor Wells
Session: Poster session 20
1407P - Characteristics and treatment sequences of patients (pts) with KRAS G12C, other KRAS and non-KRAS advanced or metastatic (AM) non-small cell lung cancer (NSCLC) in the French ESME cohort
Presenter: Nicolas Girard
Session: Poster session 20
1408P - Differences on immune biomarkers between KRAS G12C and KRAS non-G12C mutated non-small cell lung cancer
Presenter: Laura Masfarre Pinto
Session: Poster session 20
1409P - DEnosumab in combination with PD-1 checkpoint blockade for MAINtenance therapy of KRAS-mutant advanced NSCLC after first-line immunotherapy: A prospective, single-arm, phase II trial (DEMAIN)
Presenter: Hong-Shuai Li
Session: Poster session 20
1410P - Characterization of patients with advanced non-small-cell lung cancer (NSCLC) harboring KRASG12C mutation and their associated direct healthcare costs in Spanish routine clinical practice (SILK study)
Presenter: Noemi Reguart Aransay
Session: Poster session 20